EP3305285

ARAGON PHARMACEUTICALS, INC.
Application Number
EP17187458A
Filing Date
Sep 23, 2013
Status
Revoked
Aug 22, 2024
Grant Date
Sep 2, 2020
External Links
Slate, Register

Biblio Summary

The patent EP3305285B1 was granted on Sep 2, 2020 by Aragon Pharmaceuticals, Inc. The patent is currently Revoked.

The table below shows 3 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJun 2, 2021ADMISSIBLE
SYNTHON BVJun 2, 2021ADMISSIBLE
TEVAJun 2, 2021ADMISSIBLE

The table below shows the patents of Aragon Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3226843Anticancer CompositionsMay 26, 20211
EP3533792Crystalline Forms Of An Androgen Receptor ModulatorMay 5, 20211
EP3226842Anticancer CompositionsNov 25, 20202

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.